BCAX - Bicara Therapeutics Common Stock - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BCAX is currently covered by 2 analysts with an average price target of $35.24. This is a potential upside of $25.57 (264.43%) from yesterday's end of day stock price of $9.67.

Bicara Therapeutics Common Stock's activity chart (see below) currently has 0 price targets and 4 ratings on display. The stock rating distribution of BCAX is 100% BUY.

Stock Analyst Price Targets - Review

Highest price target for BCAX is $45, Lowest price target is $31, average price target is $38.

Most recent stock forecast was given by DAVID NIERENGARTEN from WEDBUSH on 12-Feb-2025. First documented stock forecast 06-Dec-2024.

Best performing analysts who are covering BCAX - Bicara Therapeutics Common Stock:

David Nierengarten Robert Burns

Currently out of the existing stock ratings of BCAX, 4 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$31

$20.16 (185.98%)

$31

4 months 5 days ago
(12-Feb-2025)

0/2 (0%)

$17.78 (134.49%)

Buy

$45

$34.16 (315.13%)

$42

4 months 21 days ago
(27-Jan-2025)

0/2 (0%)

$33.35 (286.27%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BCAX (Bicara Therapeutics Common Stock) average time for price targets to be met?

On average it took 0 days on average for the stock forecasts to be realized with a an average price target met ratio 0

Which analyst has the current highest performing score on BCAX (Bicara Therapeutics Common Stock) with a proven track record?

DAVID NIERENGARTEN

Which analyst has the current lower performing score on BCAX (Bicara Therapeutics Common Stock) with a proven track record?

ROBERT BURNS

Which analyst has the most public recommendations on BCAX (Bicara Therapeutics Common Stock)?

David Nierengarten works at WEDBUSH and has 8 price targets and 5 ratings on BCAX

Which analyst is the currently most bullish on BCAX (Bicara Therapeutics Common Stock)?

Robert Burns with highest potential upside - $34.16

Which analyst is the currently most reserved on BCAX (Bicara Therapeutics Common Stock)?

David Nierengarten with lowest potential downside - $20.16

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?